title: Tau immunotherapy and imaging.
abstract: Disappointing findings from recent phase III trials on amyloid-β (Aβ) immunotherapy for Alzheimer's disease (AD) have shifted the focus of such treatments to the tau protein. As tau pathology correlates better with the degree of dementia than Aβ plaque burden, it is a more attractive target once cognitive impairments are evident, while Aβ therapies may be better suited for the presymptomatic phase of the disease. Over 12 years ago, we initiated a tau immunotherapy program, seeking to alleviate the functional impairments associated with tau lesions in tauopathies. We have reported that various active and passive tau immunizations diminish tau pathology and improve function, including cognition, in different mouse models. Both extra- and intracellular pathways are likely involved. The antibodies may block the spread of tau pathology via microglial phagocytosis of the antibody-tau complex and facilitate lysosomal tau clearance in neurons after endosomal uptake. We have observed such antibody internalization following intracarotid injection in mice and in various culture models. These include brain slices and primary neurons from tangle mice as well as human neuroblastoma cell lines. Antibody targeting of different intracellular protein aggregates, including α-synuclein, Aβ and superoxide dismutase has been reported by others. Now, several laboratories have confirmed and extended our findings using various active and passive tau immunizations in different models, thereby clearly establishing the feasibility of this approach for clinical trials. We are also working on imaging approaches to monitor tau pathology, its consequences and the efficacy of treatments. Dire need exists for such diagnostic methods for tauopathies. Overall, therapies and diagnostic tools targeting tau pathology have a great potential for AD and other tauopathies.
authors.affiliation: Department of Neuroscience and Physiology, New York University School of Medicine, New York, N.Y., USA.
authors.forename: Einar M
authors.initials: EM
authors.lastname: Sigurdsson
mesh_terms: D000544:Alzheimer Disease / Q000628:therapy*; D000818:Animals; D006801:Humans; D007114:Immunization / Q000379:methods*; D016875:tau Proteins / Q000276:immunology*
chemical_list: D016875:tau Proteins
references.citation: J Neurochem. 2011 Aug;118(4):658-67
references.pmid: 21644996
references.citation: NMR Biomed. 2004 Dec;17(8):613-9
references.pmid: 15761950
references.citation: Neuroimage. 2013 Jan 1;64:693-702
references.pmid: 22960250
references.citation: Arch Neurol. 2006 Oct;63(10):1459-67
references.pmid: 17030663
references.citation: J Nutr Health Aging. 2013 Jan;17(1):49-50
references.pmid: 23299379
references.citation: Curr Alzheimer Res. 2012 May;9(4):397-405
references.pmid: 22272619
references.citation: J Neurosci. 2007 Aug 22;27(34):9115-29
references.pmid: 17715348
references.citation: Neuroimage. 2012 Aug 15;62(2):1208-15
references.pmid: 22406355
references.citation: JAMA Neurol. 2013 Mar 1;70(3):304-10
references.pmid: 23599928
references.citation: Exp Neurol. 2010 Aug;224(2):472-85
references.pmid: 20546729
references.citation: Brain Pathol. 2013 May;23(3):342-9
references.pmid: 23587140
references.citation: J Alzheimers Dis. 2011;26 Suppl 3:135-45
references.pmid: 21971458
references.citation: J Alzheimers Dis. 2012;31(3):601-12
references.pmid: 22683529
references.citation: Brain. 2011 Apr;134(Pt 4):1089-100
references.pmid: 21436112
references.citation: PLoS One. 2011;6(12):e26860
references.pmid: 22174735
references.citation: J Alzheimers Dis. 2013;34(2):457-68
references.pmid: 23234879
references.citation: PLoS One. 2013 Apr 29;8(4):e62402
references.pmid: 23638068
references.citation: J Neurosci. 2010 Dec 8;30(49):16559-66
references.pmid: 21147995
references.citation: Magn Reson Med. 1997 Sep;38(3):378-88
references.pmid: 9339438
references.citation: Front Psychiatry. 2011 Oct 21;2:59
references.pmid: 22025915
references.citation: Magn Reson Med. 2002 Nov;48(5):852-9
references.pmid: 12418000
references.citation: J Biol Chem. 2011 Sep 30;286(39):34457-67
references.pmid: 21841002
references.citation: J Biol Chem. 2012 Jun 1;287(23):19440-51
references.pmid: 22461630
references.citation: Pharmacol Ther. 2013 Jun;138(3):311-22
references.pmid: 23384597
references.citation: J Mol Neurosci. 2011 Nov;45(3):690-5
references.pmid: 21739165